로딩 중…
지수 로딩 중…
Parabilis Medicines Inc. Common Stock
PBLS· NASDAQ· Health Care
$36.88+1.54%
2026-09-11
Financials
Valuation Metrics
Parabilis Medicines Inc. Common Stock's Market Cap is $121M. Ranked #3069 of 3,118 in US market (top 98%), #1417 of 1,460 on NASDAQ (top 97%) by Market Cap.
Investment Metrics(as of 2026-09-11)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $121M | US#3,069/3,118 |
| Revenue | $0.00 | US#2,889/3,118 |
| Net Income | $-146M | US—/3,118 |
| Total Assets | $81M | US#3,074/3,118 |
| Net Assets | $-17M | US#2,938/3,118 |
| Employees | 145 | US#2,560/3,118 |
| Value | ||
| FCF Yield | -102.68% | US—/3,118 |
| Financial Health | ||
| Total Debt | $59M | US#2,586/3,118 |
| FCF | $-124M | US#2,683/3,118 |
| Cash | $28M | US#2,788/3,118 |
| Current Ratio | 0.52x | US#2,709/3,118 |
| Performance | ||
| 1M Return | -1.42% | US#1,032/3,118 |
| From 52W High | -11.11% | US#959/3,118 |
| 1Y MDD | -20.85% | US#781/3,118 |
| Trading | ||
| Volume | 362,328 shares | US#1,718/3,118 |
| Trading Value | $13M | US#1,699/3,118 |
| Per Share | ||
| EPS | $-44.55 | US—/3,118 |
| BPS | $-5.05 | US—/3,118 |
Company Info
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.